Last reviewed · How we verify
Bempedoic Acid Tablet
Bempedoic acid inhibits AMPK-activated protein kinase to reduce uric acid production and lower serum uric acid levels.
Bempedoic acid inhibits AMPK-activated protein kinase to reduce uric acid production and lower serum uric acid levels. Used for Chronic gout management and hyperuricemia, Gout prophylaxis in patients intolerant to or inadequately controlled by conventional urate-lowering therapy.
At a glance
| Generic name | Bempedoic Acid Tablet |
|---|---|
| Sponsor | Gan & Lee Pharmaceuticals. |
| Drug class | Uricosuric agent / Xanthine oxidase inhibitor |
| Target | AMPK (AMP-activated protein kinase) / Xanthine oxidase pathway |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Metabolic Disease |
| Phase | Phase 3 |
Mechanism of action
Bempedoic acid is a uricosuric agent that works upstream in the purine metabolism pathway by inhibiting xanthine oxidase through an indirect mechanism involving AMPK activation. It reduces serum uric acid levels by decreasing uric acid production, making it useful for chronic gout management and hyperuricemia in patients who cannot tolerate or respond to conventional xanthine oxidase inhibitors.
Approved indications
- Chronic gout management and hyperuricemia
- Gout prophylaxis in patients intolerant to or inadequately controlled by conventional urate-lowering therapy
Common side effects
- Elevated uric acid levels (transient)
- Gout flares
- Headache
- Nausea
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin (PHASE1)
- A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia (PHASE3)
- A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin (PHASE1)
- Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin (PHASE1)
- Bempedoic Acid Therapy for Polycystic Kidney Disease (PHASE2)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |